KalVista Pharmaceuticals (KALV) Insider Trading & Ownership $12.41 -0.25 (-1.97%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$12.68 +0.27 (+2.14%) As of 08/8/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KalVista Pharmaceuticals (NASDAQ:KALV) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage10.50%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$2.40MNumber OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$1.58M Get KALV Insider Trade Alerts Want to know when executives and insiders are buying or selling KalVista Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KALV Insider Buying and Selling by Quarter KalVista Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/9/2025Benjamin L PalleikoCEOSell32,979$15.69$517,440.51 6/9/2025Benjamin L PalleikoCEOSell7,169$14.50$103,950.50 5/23/2025Paul K AudhyaInsiderSell2,146$11.31$24,271.26 5/19/2025Benjamin L PalleikoCEOSell3,808$11.84$45,086.72 5/19/2025Paul K AudhyaInsiderSell2,776$11.84$32,867.84 4/9/2025Venrock Healthcare Capital ParMajor ShareholderBuy25,000$9.42$235,500.00 3/7/2025Benjamin L PalleikoCEOSell6,669$11.97$79,827.93 2/24/2025Paul K AudhyaInsiderSell2,394$10.02$23,987.88 2/18/2025Benjamin L PalleikoCEOSell5,104$9.82$50,121.28 2/18/2025Paul K AudhyaInsiderSell3,125$9.82$30,687.50 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 2/12/2025Venrock Healthcare Capital ParMajor ShareholderBuy100,000$9.23$923,000.00 2/10/2025Venrock Healthcare Capital ParMajor ShareholderBuy4,137$9.14$37,812.18 2/7/2025Venrock Healthcare Capital ParMajor ShareholderBuy73,649$9.29$684,199.21 2/3/2025Venrock Healthcare Capital ParMajor ShareholderBuy14,562$9.22$134,261.64 1/30/2025Venrock Healthcare Capital ParMajor ShareholderBuy43,707$8.76$382,873.32 12/9/2024Benjamin L PalleikoCEOSell7,627$9.75$74,363.25 11/26/2024Paul K AudhyaInsiderSell2,187$9.87$21,585.69 11/18/2024Benjamin L PalleikoCEOSell14,400$9.26$133,344.00 11/18/2024Paul K AudhyaInsiderSell8,077$9.26$74,793.02 9/9/2024Benjamin L PalleikoCEOSell7,352$12.19$89,620.88 8/23/2024Paul K AudhyaInsiderSell2,135$12.40$26,474.00 8/19/2024Benjamin L PalleikoCEOSell14,215$12.01$170,722.15 8/19/2024Christopher YeaInsiderSell7,102$12.01$85,295.02 (Data available from 1/1/2013 forward) KALV Insider Trading Activity - Frequently Asked Questions Who is on KalVista Pharmaceuticals' Insider Roster? The list of insiders at KalVista Pharmaceuticals includes Albert Cha, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Paul K Audhya, Thomas Andrew Crockett, and Venrock Healthcare Capital Par. Learn more on insiders at KALV. What percentage of KalVista Pharmaceuticals stock is owned by insiders? 10.50% of KalVista Pharmaceuticals stock is owned by insiders. Learn more on KALV's insider holdings. Which KalVista Pharmaceuticals insiders have been buying company stock? The following insider purchased KALV shares in the last 24 months: Venrock Healthcare Capital Par ($8,203,926.65). How much insider buying is happening at KalVista Pharmaceuticals? Insiders have purchased a total of 709,577 KALV shares in the last 24 months for a total of $8,203,926.65 bought. Which KalVista Pharmaceuticals insiders have been selling company stock? The following insiders have sold KALV shares in the last 24 months: Albert Cha ($189,000.00), Benjamin L Palleiko ($2,070,731.64), Christopher Yea ($85,295.02), Edward P Feener ($1,012,679.62), Paul K Audhya ($320,721.79), and Thomas Andrew Crockett ($871,389.16). How much insider selling is happening at KalVista Pharmaceuticals? Insiders have sold a total of 366,618 KalVista Pharmaceuticals shares in the last 24 months for a total of $4,549,817.23 sold. KalVista Pharmaceuticals Key ExecutivesMr. Benjamin L. Palleiko (Age 58)CEO & Director Compensation: $983.07k5 recent tradesDr. Christopher M. Yea Ph.D. (Age 60)Chief Development Officer Compensation: $708.53kDr. Paul K. Audhya M.B.A. (Age 51)M.D., Chief Medical Officer Compensation: $736.82kMr. Brian Piekos (Age 49)Chief Financial Officer Mr. Ryan BakerHead of Investor RelationsMr. Brian Krex J.D. (Age 56)General Counsel Jarrod AldomVice President of Corporate CommunicationsMs. Rachel M. MortenSenior Vice President of Regulatory Affairs & QADr. Michael D. Smith Pharm.D. (Age 44)Senior Vice President of Development Ms. Nicole Sweeny (Age 48)Chief Commercial Officer More Insider Trading Tools from MarketBeat Related Companies CRNX Insider Selling IMVT Insider Selling OGN Insider Selling NAMS Insider Selling RXRX Insider Selling GMTX Insider Selling RARE Insider Selling MIRM Insider Selling CPRX Insider Selling AMRX Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:KALV) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALV Stock Alerts